Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

OLANZAPINE EMBONATE MONOHYDRATE CRS (10 MG)

OLANZAPINE EMBONATE MONOHYDRATE CRS (10 MG)

ND

DISCOVER
MEXILETINE IMPURITY A CRS (40MG)

MEXILETINE IMPURITY A CRS (40MG)

ND

DISCOVER
OLANZAPINE EMBONATE FOR PEAK IDENTIFICATION CRS (10 MG)

OLANZAPINE EMBONATE FOR PEAK IDENTIFICATION CRS (10 MG)

ND

DISCOVER
CLOMIFENE FOR SYSTEM SUITABILITY CRS (25 MG)

CLOMIFENE FOR SYSTEM SUITABILITY CRS (25 MG)

ND

DISCOVER
PROTAMINE SULFATE CRS (3 MG)

PROTAMINE SULFATE CRS (3 MG)

9009-65-8

DISCOVER
CLOMIFENE CITRATE FOR ID AND ASSAY CRS (70 MG)

CLOMIFENE CITRATE FOR ID AND ASSAY CRS (70 MG)

ND

DISCOVER
CYASTERONE  CRS (10 MG)

CYASTERONE CRS (10 MG)

ND

DISCOVER
TRIFLURIDINE CRS (60 MG)

TRIFLURIDINE CRS (60 MG)

ND

DISCOVER
ISOVITEXIN CRS (15 MG)

ISOVITEXIN CRS (15 MG)

ND

DISCOVER
LETROZOLE IMPURITY A CRS (0.5µG)

LETROZOLE IMPURITY A CRS (0.5µG)

ND

DISCOVER
KETOCONAZOLE IMPURITY MIXTURECRS (0.03 MG)

KETOCONAZOLE IMPURITY MIXTURECRS (0.03 MG)

ND

DISCOVER
DRONEDARONE  IMPURITY A CRS (10 MG)

DRONEDARONE IMPURITY A CRS (10 MG)

ND

DISCOVER